Aerovate Therapeutics Analyst Ratings
Aerovate Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/06/2022 | 73.63% | BTIG | → $27 | Upgrades | Neutral → Buy |
| 08/16/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 02/11/2022 | 54.34% | BTIG | → $24 | Initiates Coverage On | → Buy |
| 07/26/2021 | 92.93% | Evercore ISI Group | → $30 | Initiates Coverage On | → Outperform |
| 07/26/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/26/2021 | 47.91% | Wedbush | → $23 | Initiates Coverage On | → Outperform |
| 07/26/2021 | 35.05% | Jefferies | → $21 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 12/06/2022 | 73.63% | BTIG | → $27 | 升级 | 中性→购买 |
| 08/16/2022 | — | BTIG | 评级下调 | 购买→中性 | |
| 02/11/2022 | 54.34% | BTIG | → $24 | 开始承保 | →购买 |
| 07/26/2021 | 92.93% | Evercore ISI集团 | → $30 | 开始承保 | →跑赢大盘 |
| 07/26/2021 | — | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 07/26/2021 | 47.91% | 韦德布什 | → $23 | 开始承保 | →跑赢大盘 |
| 07/26/2021 | 35.05% | 杰富瑞 | → $21 | 开始承保 | →购买 |
What is the target price for Aerovate Therapeutics (AVTE)?
Aerovate Treeutics(AVTE)的目标价格是多少？
The latest price target for Aerovate Therapeutics (NASDAQ: AVTE) was reported by BTIG on December 6, 2022. The analyst firm set a price target for $27.00 expecting AVTE to rise to within 12 months (a possible 73.63% upside). 3 analyst firms have reported ratings in the last year.
BTIG于2022年12月6日报道了Aerovate治疗公司(纳斯达克：AVTE)的最新目标价。这家分析公司将目标价定为27美元，预计中兴通讯将在12个月内上涨至73.63%(可能上涨73.63%)。3家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Aerovate Therapeutics (AVTE)?
Aerovate Treeutics(AVTE)的最新分析师评级是什么？
The latest analyst rating for Aerovate Therapeutics (NASDAQ: AVTE) was provided by BTIG, and Aerovate Therapeutics upgraded their buy rating.
对Aerovate Treateutics(纳斯达克股票代码：AVTE)的最新分析师评级由北欧国际集团提供，Aerovate治疗公司上调了买入评级。
When is the next analyst rating going to be posted or updated for Aerovate Therapeutics (AVTE)?
Aerovate治疗公司(AVTE)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aerovate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aerovate Therapeutics was filed on December 6, 2022 so you should expect the next rating to be made available sometime around December 6, 2023.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Aerovate治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Aerovate治疗公司的上一次评级是在2022年12月6日提交的，所以你应该预计下一次评级将在2023年12月6日左右提供。
Is the Analyst Rating Aerovate Therapeutics (AVTE) correct?
分析师对Aerovate Treeutics(AVTE)的评级正确吗？
While ratings are subjective and will change, the latest Aerovate Therapeutics (AVTE) rating was a upgraded with a price target of $0.00 to $27.00. The current price Aerovate Therapeutics (AVTE) is trading at is $15.55, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Aerovate治疗(AVTE)评级被上调，目标价从0.00美元到27.00美元。Aerovate治疗公司(AVTE)目前的交易价格为15.55美元，在分析师的预测范围内。